Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27847741 | 0.88 | MCHR1 (0.52) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL27580577 | 0.88 | MCHR1 (0.52) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL27824379 | 0.88 | MCHR1 (0.52) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL4190945 | 0.80 | MAPT (0.53) | MCHR1L3MBTL3HRH3 | |
| SCHEMBL27781047 | 0.80 | L3MBTL3 (0.60) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL2883532 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL21464535 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL8159119 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL1196740 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3KDM1AMAOAMAOB | |
| SCHEMBL2883536 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | MCHR1 4663/4885L3MBTL3 4003/4885KDM1A 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.